These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 33984688)

  • 21. Awareness and Perceived Effectiveness of HIV Treatment as Prevention Among Men Who Have Sex with Men in New York City.
    Siegel K; Meunier É
    AIDS Behav; 2019 Jul; 23(7):1974-1983. PubMed ID: 30697639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Achieving the "Ending the HIV Epidemic in the U.S." incidence reduction goals among at-risk populations in the South.
    Hamilton DT; Hoover KW; Smith DK; Delaney KP; Wang LY; Li J; Hoyte T; Jenness SM; Goodreau SM
    BMC Public Health; 2023 Apr; 23(1):716. PubMed ID: 37081482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of combination prevention strategies on HIV incidence among gay and bisexual men who have sex with men in the UK: a model-based analysis.
    Cambiano V; Miners A; Lampe FC; McCormack S; Gill ON; Hart G; Fenton KA; Cairns G; Thompson M; Delpech V; Rodger AJ; Phillips AN
    Lancet HIV; 2023 Nov; 10(11):e713-e722. PubMed ID: 37923485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China.
    Zhang L; Peng P; Wu Y; Ma X; Soe NN; Huang X; Wu H; Markowitz M; Meyers K
    AIDS Behav; 2019 Feb; 23(2):523-533. PubMed ID: 29971734
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel method to estimate the indirect community benefit of HIV interventions using a microsimulation model of HIV disease.
    Kazemian P; Costantini S; Neilan AM; Resch SC; Walensky RP; Weinstein MC; Freedberg KA
    J Biomed Inform; 2020 Jul; 107():103475. PubMed ID: 32526280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany.
    Jansen K; Steffen G; Potthoff A; Schuppe AK; Beer D; Jessen H; Scholten S; Spornraft-Ragaller P; Bremer V; Tiemann C;
    BMC Infect Dis; 2020 Feb; 20(1):110. PubMed ID: 32033533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India.
    Kazemian P; Costantini S; Kumarasamy N; Paltiel AD; Mayer KH; Chandhiok N; Walensky RP; Freedberg KA
    Clin Infect Dis; 2020 Feb; 70(4):633-642. PubMed ID: 30921454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamicity of HIV Pre-exposure Prophylaxis Usage Pattern and Association with Executed Adherence in MSM: An Implementation Study in Hong Kong.
    Wong NS; Chan DP; Kwan TH; Lui GC; Lee KC; Lee SS
    AIDS Behav; 2024 Apr; 28(4):1327-1344. PubMed ID: 37775644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-exposure prophylaxis (PrEP) for MSM in low HIV incidence places: should high risk individuals be targeted?
    Wong NS; Kwan TH; Tsang OTY; Lee MP; Yam WC; Lam W; Leung WS; Chan JMC; Ho KM; Lee SS
    Sci Rep; 2018 Aug; 8(1):11641. PubMed ID: 30076362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness and impact of pre-exposure prophylaxis to prevent HIV among men who have sex with men in Asia: A modelling study.
    Ten Brink DC; Martin-Hughes R; Minnery ME; Osborne AJ; Schmidt HA; Dalal S; Green KE; Ramaurtarsing R; Wilson DP; Kelly SL
    PLoS One; 2022; 17(5):e0268240. PubMed ID: 35617169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Impact of the 90-90-90 goal and pre-exposure prophylaxis on HIV transmission and elimination in men who have sex with men in China: A mathematical modeling study].
    Wang KR; Peng LP; Gu J; Hao C; Zou HC; Hao YT; Li JH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Nov; 39(11):1507-1514. PubMed ID: 30462963
    [No Abstract]   [Full Text] [Related]  

  • 33. Community awareness of, use of and attitudes towards HIV pre-exposure prophylaxis (PrEP) among men who have sex with men in Vancouver, Canada: preparing health promotion for a publicly funded PrEP program.
    Lachowsky NJ; Lawson Tattersall T; Sereda P; Wang C; Edwards J; Hull M
    Sex Health; 2019 Apr; 16(2):180-186. PubMed ID: 31040001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reasons for not using pre-exposure prophylaxis for HIV and strategies that may facilitate uptake in Ontario and British Columbia among gay, bisexual and other men who have sex with men: a cross-sectional survey.
    Pico-Espinosa OJ; Hull M; MacPherson P; Grace D; Lachowsky N; Gaspar M; Mohammed S; Truong R; Tan DHS
    CMAJ Open; 2023; 11(3):E560-E568. PubMed ID: 37369522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of and Factors Associated with the Use of HIV Serosorting and Other Biomedical Prevention Strategies Among Men Who Have Sex with Men in a US Nationwide Survey.
    Grov C; Jonathan Rendina H; Patel VV; Kelvin E; Anastos K; Parsons JT
    AIDS Behav; 2018 Aug; 22(8):2743-2755. PubMed ID: 29550942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.
    Grulich AE; Guy R; Amin J; Jin F; Selvey C; Holden J; Schmidt HA; Zablotska I; Price K; Whittaker B; Chant K; Cooper C; McGill S; Telfer B; Yeung B; Levitt G; Ogilvie EE; Dharan NJ; Hammoud MA; Vaccher S; Watchirs-Smith L; McNulty A; Smith DJ; Allen DM; Baker D; Bloch M; Bopage RI; Brown K; Carr A; Carmody CJ; Collins KL; Finlayson R; Foster R; Jackson EY; Lewis DA; Lusk J; O'Connor CC; Ryder N; Vlahakis E; Read P; Cooper DA;
    Lancet HIV; 2018 Nov; 5(11):e629-e637. PubMed ID: 30343026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ending risk-group HBV vaccination for MSM after the introduction of universal infant HBV vaccination: A mathematical modelling study.
    Xiridou M; Visser M; Urbanus A; Matser A; van Benthem B; Veldhuijzen I
    Vaccine; 2021 May; 39(21):2867-2875. PubMed ID: 33896665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM.
    Estcourt C; Yeung A; Nandwani R; Goldberg D; Cullen B; Steedman N; Wallace L; Hutchinson S
    AIDS; 2021 Mar; 35(4):665-673. PubMed ID: 33290298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada.
    Lima VD; Brumme ZL; Brumme C; Sereda P; Krajden M; Wong J; Guillemi SA; Henry B; Hogg RS; Barrios R; Montaner JSG;
    Curr HIV/AIDS Rep; 2020 Apr; 17(2):77-87. PubMed ID: 32124189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High HIV risk and syndemic burden regardless of referral source among MSM screening for a PrEP demonstration project in Toronto, Canada.
    Wilton J; Noor SW; Schnubb A; Lawless J; Hart TA; Grennan T; Fowler S; Maxwell J; Tan DHS
    BMC Public Health; 2018 Feb; 18(1):292. PubMed ID: 29486737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.